Work

Clinical investigation of pharmaceutical and lifestyle interventions in persons with chronic kidney disease

Year: 2024
Type: dissertation
Abstract: Chronic kidney disease (CKD) leading to kidney failure and end-stage renal disease (ESRD) is aserious medical condition associated with increased morbidity, mortality, and in particular\ncardiovascular disease (CVD) risk. CKD is characterized by a range of complex deleterious\nphysiological and metabolic function alterations including disruptions in lipid, amino acid, and\ncarbohydrate metabolism; skeletal muscle dysfunction, insulin resistance, and heightened\ninflammation/oxidative stress. In addition, concurrent comorbidities such as diabetes,\nhypertension, and dyslipidemia further exacerbate cardiometabolic risk and worsen patient\noutcomes. Emerging evidence suggest that dysfunctional mitochondria have a pivotal role in both\nthe development of CKD and its associated comorbidities highlighting it as a promising target for\ntherapeutic intervention. The goal of my work was to comprehensively explore the diverse\npathophysiologies linked to CKD, its nutritional implications, and treatment modalities; and the\npotential to modify health and outcome by pharmacological and non-pharmacological means. By\nelucidating the interplay between CKD and metabolic derangements, as well as the impact of\nmitochondrial dysfunction, we aimed to pave the way for novel therapeutic approaches that\naddress management of CKD and improve patient prognosis.\nIn this dissertation, we have focused on patient-oriented research using metabolic imaging and\nmulti-omics approaches to better understand the pathophysiology of CKD and linking alterations\nin metabolism with muscle function and physical performance. In doing so, we performed a\n2\ncomprehensive investigation of metabolic, physiological, and cardiometabolic disturbances in\nCKD. Chapter 1 provides a comprehensive overview of CKD and CKD-related comorbidities as\nwell as metabolic and physiological complications. Chapter 2 investigates the impact of\nnicotinamide riboside (NR) and coenzyme Q10 (CoQ10) that target mitochondrial metabolism for\ntheir potential effects on systemic markers of mitochondrial metabolism and physical endurance\nin a sedentary CKD cohort. Chapter 3 and 4 investigate metabolic derangements in non-diabetic\nmoderate-severe CKD. Chapter 3 focuses on identifying altered metabolic pathways contributing\nto disruptions to insulin response in response to oral glucose tolerance testing in CKD. In chapter\n4 we build on the findings from chapter 3 by investigating postprandial incretin hormone levels\nand their determinants using a standardized OGTT comparing non-diabetic patients with CKD and\ncontrols. We separately investigate the association of postprandial circulating incretin hormones\nwith insulin, c-peptide, and glucagon levels during an OGTT by CKD status. Chapter 5 provides\na summary of the work performed, concluding remarks, and plans for future studies.
Author: Ahmadi, Armin
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: green
OpenAlex ID: W7008718299
Cites: 157
Cited by:
Related to: 10